Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer

被引：127

作者：

Stewart, HJ

Forrest, AP

Everington, D

McDonald, CC

Dewar, JA

Hawkins, RA

Prescott, RJ

George, WD

机构：

[1] UNIV EDINBURGH,DEPT CLIN SURG,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND

[2] INFORMAT & STAT DIV,EDINBURGH EH5 3SQ,MIDLOTHIAN,SCOTLAND

[3] NINEWELLS HOSP & MED SCH,DUNDEE DD1 9SY,SCOTLAND

[4] UNIV EDINBURGH,ROYAL INFIRM,NHS TRUST,DEPT SURG,LISTER RES LABS,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND

[5] UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,MED STAT UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND

[6] UNIV GLASGOW,WESTERN INFIRM,DEPT SURG,GLASGOW G1 6NT,LANARK,SCOTLAND

来源：

BRITISH JOURNAL OF CANCER | 1996年 / 74卷 / 02期

关键词：

breast cancer; long-term tamoxifen; randomised trial;

D O I：

10.1038/bjc.1996.356

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In 1985 a second randomisation was initiated for women in the treatment arm of the Scottish Tamoxifen Trial either to stop tamoxifen at 5 years or to continue indefinitely. A preliminary analysis of outcome in 342 patients al a median follow-up of 6 years suggests that a worthwhile gain in disease control from continuing adjuvant tamoxifen beyond 5 years is unlikely. [Hazard ratio for events (relapse or death without relapse) is 1.27, 95% CI=0.87-1.85.] There is a suggestion that therapy for longer than 5 years may increase the risk of endometrial carcinoma (P = 0.064).

引用

页码：297 / 299

页数：3